No Data
AKESO: 2024 ANNUAL REPORT
BOCOM INTL: Maintain AKESO "Buy" rating, Target Price 115 HKD.
BOCOM INTL released a Research Report stating a bullish outlook on AKESO (09926), maintaining a 'Buy' rating and a Target Price of HKD 115. The bank maintains its forecast for the domestic and overseas peak sales of Aivyasu at 6.1 billion yuan. The company announced that the application for the domestic listing of Aivyasu monoclonal antibody for the treatment of LPD-L1 positive NSCLC has been successfully approved, much earlier than expected. At the same time, it released the first interim analysis results of the Phase III AK112-303/HARMONi-2 study: HR value of 0.777, reducing the risk of death by 22.3%. The bank believes that the α value obtained from this interim analysis is relatively low, and the sample...
[Brokerage Focus] BOCOM INTL maintains a Buy rating on AKESO (09926), pointing out that the overseas development prospects of Ivosidenib remain optimistic.
Jinwu Finance | BOCOM INTL issued a Research Report stating that AKESO (09926) announced the successful approval of its application for listing in mainland China for the treatment of 1L PD-L1 positive NSCLC with evosetinib, much earlier than expected. It also disclosed the first interim analysis results of the Phase III AK112-303/HARMONi-2 study: a hazard ratio of 0.777, indicating a 22.3% reduction in mortality risk. The institution believes that the low alpha value and small sample size from this interim analysis means the market should pay more attention to the results of the second and final overall survival analysis. The study has obtained full clinical approval in mainland China.
Capital trends | North funds frantically buying AKESO at 0.779 billion, selling Alibaba and Tencent.
Goldman Sachs has raised its forecast for this year's Inflow from the north into Hong Kong stocks to 110 billion US dollars.
Nomura Downgrades Akeso to Neutral From Buy, Adjusts Price Target to HK$99.66 From HK$75.14
Citi is bullish on the China Medical Health Sector, with AI empowerment driving Ping An Healthcare (01833) to become the preferred stock.
Citi is bullish on the Chinese Medical and health sector, with Ping An Health and others as preferred stocks.
AzonAdam : overbought. Gap needs to be filled.
Saywallahcuzzy OP AzonAdam : fair enough. sounds like BYD
what's the fair price? the FDA approval is a big deal and in future this stock will go up